For active psoriatic arthritis (PsA) in adult TNFi-IR patients1

Powerful disease
control2

RINVOQ achieved its ranked secondary endpoint of Minimal Disease Activity at Week 24, with response rates up to ~1 year2,3

IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor

RINVOQ achieved its ranked secondary endpoint of Minimal Disease Activity at Week 24, with response rates up to ~1 year2,3

IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor

Clinical Trial Overview

SELECT-PsA 2 Clinical Trial Overview

*P<0.001 RINVOQ vs placebo2

SELECT-PsA 2 Study Design Intro:1

24-week, double-blind, placebo-controlled study of 642 adult patients with moderate to severe active PsA who had an inadequate response or intolerance to at least one biologic DMARD. Patients were randomized to receive upadacitinib or placebo. The primary endpoint was proportion of patients achieving ACR20 response at Week 12 vs placebo.

ACR=American College of Rheumatology; ACR20=improvement of at least 20% in tender joint count, swollen joint count, and at least 3 of the 5 other core criteria, including patient and physician global assessments, health assessment questionnaire — disability index (HAQ‑DI), pain assessment, and high‑sensitivity C‑reactive protein (hs‑CRP); bDMARD=biologic disease‑modifying antirheumatic drug; DMARD=disease‑modifying antirheumatic drug; IR=intolerance or inadequate response; NRI=non‑responder imputation; PsA=psoriatic arthritis; QD=once per day; TNFi=tumor necrosis factor inhibitor

Minimal disease activity ACHIEVED
AT WEEK 24 WITH RESPONSE RATES
at WEEK 562,3

Minimal Disease Activity (MDA) is achieved when meeting 5 of 7 criteria:4

  • Tender joint count ≤1
  • Swollen joint count ≤1
  • PASI ≤1 or BSA-Psoriasis ≤3%
  • Pain NRS ≤1.5 (0—10 NRS)
  • Patient Global Disease Activity NRS ≤2 (0—10 NRS)
  • HAQ-DI ≤0.5
  • LEI ≤1

Get a summary of
the MDA data

SELECT-PsA 2: MDA over time3

A study in biologic DMARD-IR patients

RINVOQ is indicated for TNFi-IR patients

SELECT-PsA 2: MDA over time2

A study in biologic DMARD-IR patients

RINVOQ is indicated for TNFi-IR patients

SELECT-PsA 1: MDA over time SELECT-PsA 1: MDA over time SELECT-PsA 1: MDA over time

~25% of RINVOQ patients achieved MDA at Week 243,*

Nearly 30% of RINVOQ patients achieved MDA at ~1 year3

Data LIMITATIONS:4 Data labeled as a ranked secondary endpoint were multiplicity controlled for comparisons. All other comparisons were not adjusted for multiplicity; therefore, statistical significance has not been established.

~25% of RINVOQ patients achieved MDA at Week 243,*

Nearly 30% of RINVOQ patients achieved MDA at ~1 year3

RINVOQ SAFETY DATA

Review the safety profile of RINVOQ,
including both short- and long-term analyses